Full-Time

Group Leader

Drug Product Analytics

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$150k - $174kAnnually

Senior, Expert

San Carlos, CA, USA

This position requires onsite presence in San Carlos, California.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • MSc in Pharmaceutics, Chemistry, Biophysics or Biochemistry preferred, with >10 years of industrial experience; or PhD in Pharmaceutics, Chemistry, Biophysics or Biochemistry with > 5 years of relevant experience.
  • The candidate will have had strong experience in characterization of Biological Drug Products containing proteins, polysaccharides and/or protein conjugate formulations. Experience in characterization of vaccine systems containing adjuvants will be an advantage.
  • Experience of testing within GxP environments either directly or through CMOs.
  • Strong experience in method development for HPLC (SEC, RP, AEX, HPAEC-PAD) based assays, particle light scattering analysis (DLS, MALS), quantitative subvisible particle analysis (MFI, Laser Diffraction), visible analysis, is required.
  • Demonstrated experience in authoring analytical technical documents, including method protocols and SOPs, assay transfer and implementation protocols and reports, validation protocols and reports.
  • Participated in method transfers to external vendors and to internal collaborators.
  • Strong scientific leadership is required: critical thinking, ability to present complex data sets and to independently propose and design follow-up experiments.
  • Managerial experience is of notable benefit.
  • The candidate should have high degrees of both flexibility and organizational skills as well as an eagerness and ability to learn to effectively navigate Vaxcyte’s multiple projects and timelines.
  • Strong interpersonal skills, ability to communicate effectively both verbally and in written formats are necessary to collaborate effectively with the rest of the Drug Product Development team and well as across other teams.
  • Detail oriented, rigorous and excellent skills in record keeping.
Responsibilities
  • Leading analytical method development and execution for Drug Product characterization.
  • Lead (direct management) a team of scientists to support process development activities, formulation selection and stability analysis of Drug Product and/or Intermediate and Drug Substance materials.
  • Evaluate and develop the most appropriate biochemical and biophysical characterization tools to support biological drug product development, including adjuvanted vaccine drug products.
  • Apply biophysical characterization techniques to fully understand antigen/adjuvant interactions and to assess formulation matrix optimization options.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA for adult use. Vaxcyte employs advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while eliciting a strong immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial infections on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

19%

1 year growth

61%

2 year growth

129%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.

Help us improve and share your feedback! Did you find this helpful?